TD Private Client Wealth’s Core Laboratories CLB Stock Holding History

TD Private Client Wealth’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$786	Buy	+81	New	+$938	﹤0.01%	1592

Other funds holding CLB

Evergreen Capital Management Bellevue, Washington $5.65B AUM 21.62% 1-Year Est. Return

CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return

Oppenheimer Asset Management New York $9.5B AUM 23.46% 1-Year Est. Return

Isthmus Partners Madison, Wisconsin $1.04B AUM 19.97% 1-Year Est. Return

PWMAG

Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.71B AUM 23.29% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Harpswell Capital Advisors Yarmouth, Maine $152M AUM 8.39% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

TD Private Client Wealth's CLB Position: Q3 2026 in Review

TD Private Client Wealth opened a new position in Core Laboratories (CLB) in Q3 2026: 81 shares worth $786. The stake represents ﹤0.01% of the portfolio and ranks #1592 among its holdings.

31 funds tracked by Wall St. Rank hold CLB as of Q3 2026.

TD Private Client Wealth held 81 shares of Core Laboratories worth $786 as of Q3 2026.
Core Laboratories was a new TD Private Client Wealth position in Q3 2026.
Core Laboratories made up ﹤0.01% of TD Private Client Wealth's portfolio in Q3 2026, its #1592 holding.
31 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2026.

Based on TD Private Client Wealth's 13F filing for Q3 2026, filed 28 Oct 2026.